Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 8916 results

  1. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development Reference number: GID-TA11523 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development Reference number: GID-TA10826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  10. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Discontinued Reference number: GID-TA11411

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    In development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]

    In development Reference number: GID-TA11884 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued Reference number: GID-TA10375

    Technology appraisal guidance
    Discontinued